Fidasimtamab is a recombinant human IgG1 bispecific antibody with potential immunosuppressive and antitumor activities; it simultaneously targets, binds to, and inhibits HER2 and PD-1 and their downstream signaling pathways, and bridges PD-1-expressing T cells with HER2-expressing tumor cells.